Rare Biomarkers Specimen Collection And Stabilization Market To Reach $92.39 Billion By 2030

December 2024 | Report Format: Electronic (PDF)

Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.


key Request a free sample copy or view report summary: Rare Biomarkers Specimen Collection And Stabilization Market Report


Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights

  • The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.

  • The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.

  • The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.

  • North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.

Rare Biomarkers Specimen Collection And Stabilizations Market Segmentation

Grand View Research has segmented the global rare biomarkers specimen collection and stabilization market on the basis of biomarker, end use, and region:

Rare Biomarkers Specimen Collection And Stabilizations Biomarker Outlook (Revenue, USD Million, 2018 - 2030)

  • Circulating Cell Free DNA (ccfDNA)

  • Circulating Tumor Cells (CTCs)

  • Exosomes/Extracellular Vesicles

    • By Product

      • Isolation Kits & Reagents

      • Blood Collection Tubes

      • Systems

    • By Specimen Type

      • Serum/Plasma

      • Others

    • By Nucleic Acid & Other Biomolecules

      • RNA

      • DNA

      • Others

    • By Application

      • NIPT

      • Oncology

        • Research

        • Diagnostics

          • Screening

          • Treatment Monitoring

      • Transcriptomics

      • Pharmacogenomics

      • Transplant Rejection

      • Population Screening

      • Cardiovascular Diseases

      • Other Applications

  • Circulating Cell Free RNA (ccfRNA) / miRNA

    • By Product

      • Isolation Kits & Reagents

      • Blood Collection Tubes

    • By Application

      • NIPT

      • Oncology

        • Research

        • Diagnostics

      • Transcriptomics

      • Pharmacogenomics

      • Transplant Rejection

      • Population Screening

      • Cardiovascular Diseases

      • Other Applications

Rare Biomarkers Specimen Collection And Stabilizations End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Research

    • Research Labs/CROs

    • Academic Institutes

  • Diagnostics

    • Laboratories

    • Hospitals

    • Prenatal Clinics

Rare Biomarkers Specimen Collection And Stabilizations Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

List of Key Players of Rare Biomarkers Specimen Collection And Stabilizations Market

  • QIAGEN

  • Charles River Laboratories

  • F. Hoffmann-La Roche Ltd

  • Thermo fischer Scientific Inc.

  • Eurofins Scientific

  • PerkinElmer Inc.

  • Bio-Rad Laboratories, Inc.

  • Agilent Technologies, Inc

  • Merck KGaA

  • Siemens Healthcare GmbH

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.